Roche Holding AG Basel American Depositary Shares (RHHBY)
39.67
+0.59 (1.51%)
OP · Last Trade: May 24th, 10:21 AM EDT
Detailed Quote
Previous Close | 39.08 |
---|---|
Open | 39.03 |
Bid | - |
Ask | - |
Day's Range | 39.02 - 39.79 |
52 Week Range | 31.19 - 44.31 |
Volume | 952,705 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 2,280,191 |
Chart
News & Press Releases
The company said that the European Commission is expected to make a decision soon regarding the approval for Itovebi.
Via Stocktwits · May 23, 2025
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year follow-up data from the Phase III STARGLO study. After a median follow-up of 24.7 months, data showed a 40% improvement in overall survival (OS) for patients treated with Columvi® (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) and median OS was not reached, compared to 13.5 months for Rituxan® (rituximab) plus GemOx (R-GemOx). These updated data continue to demonstrate the statistically significant and clinically meaningful survival benefit of this off-the-shelf, fixed-duration Columvi combination for people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant (ASCT). Data will be presented in an oral session at the 61st American Society of Clinical Oncology (ASCO), May 30 – June 3, 2025.
By Genentech · Via Business Wire · May 23, 2025
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic retinopathy (DR), a potentially blinding condition that affects almost 10 million people in the U.S. and more than 100 million people globally. It is the first and only FDA-approved continuous delivery treatment shown to maintain vision in people with DR with just one refill every nine months. Susvimo is now available to U.S. retina specialists and their patients with DR who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections.
By Genentech · Via Business Wire · May 22, 2025
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) discussed the supplemental Biologics License Application (sBLA) for Columvi® (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not candidates for autologous stem cell transplant (ASCT).
By Genentech · Via Business Wire · May 20, 2025
Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.
Via Investor's Business Daily · May 16, 2025
Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.
Via Benzinga · May 15, 2025
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.
Via Benzinga · May 14, 2025
FDA grants accelerated approval to AbbVie's Emrelis for c-Met overexpressing NSCLC; siRNA partnership with ADARx includes $335 million upfront.
Via Benzinga · May 14, 2025
Roche's APHINITY study shows promising results for HER2-positive breast cancer treatment with Perjeta regime
Via Benzinga · May 13, 2025
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit and Frontier Science Foundation, announced today statistically significant final overall survival (OS) results from the Phase III APHINITY study in people with human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer. After ten years, the risk of death was reduced by 17% for people treated with Perjeta® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for a year as post-surgery (adjuvant) treatment, compared with individuals who received Herceptin, chemotherapy, and placebo.
By Genentech · Via Business Wire · May 13, 2025
JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting its near-term impact on pharma stocks.
Via Stocktwits · May 12, 2025
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices.
Via Investor's Business Daily · May 12, 2025
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today plans to invest more than $700 million in a new 700,000 square foot state-of-the-art drug manufacturing facility in Holly Springs, NC.
By Genentech · Via Business Wire · May 12, 2025
Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space.
Via Benzinga · May 12, 2025
What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription drug prices.
Via Benzinga · May 12, 2025
Sarepta stock plummeted Wednesday on a "double whammy" that includes its trimmed 2025 sales outlook and a critical FDA appointment.
Via Investor's Business Daily · May 7, 2025
FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing.
Via Benzinga · May 6, 2025
See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion.
Via MarketBeat · April 28, 2025
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the New England Journal of Medicine (NEJM) has published a detailed analysis of the Phase III CENTERSTONE trial of Xofluza® (baloxavir marboxil). The trial met its primary endpoint, showing a single, oral dose of Xofluza taken by people infected with influenza reduced the odds of untreated household members contracting the virus by 32%. For the key secondary endpoint of influenza virus transmission resulting in symptoms, Xofluza showed a clinically meaningful reduction although statistical significance was not reached. Xofluza was well tolerated, with no new safety signals identified.
By Genentech · Via Business Wire · April 25, 2025
Roche rode its pharmaceuticals growth to a sales beat, while Sanofi's report was more complicated.
Via Investor's Business Daily · April 24, 2025
Roche to invest $50 billion in U.S. over five years, adding 12,000+ jobs and expanding manufacturing, R&D, and export capacity across eight states.
Via Benzinga · April 22, 2025
Roche plans $50B investment in U.S. for manufacturing & research, as potential drug tariffs loom. Move to create 12,000 jobs & increase exports
Via Benzinga · April 22, 2025